Quince Therapeutics Presents Preclinical Data at ASBMR 2022 Demonstrating Application of Bone-targeting Platform for Spinal Fusion and Bone Cancer Indications
September 12 2022 - 7:00AM
Business Wire
Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical
company advancing innovative precision therapeutics targeting
debilitating and rare diseases, today detailed highlights from the
company’s participation at The American Society for Bone and
Mineral Research Annual Meeting (ASBMR 2022), which took place
September 9 to September 12, 2022, in Austin, Texas. At ASBMR 2022,
Quince presented two posters showcasing the broad applicability of
the company’s highly differentiated bone-targeting platform and
potential to accelerate healing directly at the site of bone injury
and disease in spinal fusion and bone cancer indications.
Stewart Low, Quince’s head of discovery, said, “Supported by
more than 10 years of extensive preclinical studies, we believe
Quince’s proprietary bone-targeting platform can be harnessed to
enable the precise delivery of drug concentrated directly to the
site of bone injury and disease to accelerate healing. We are
excited to continue to bring our preclinical research forward to
demonstrate the potential of our proprietary targeting platform
with additional indications in spinal fusion and bone cancer as we
seek to improve outcomes in underserved patient populations.”
ASBMR 2022 Poster Highlights
The following are highlights from the company’s poster
presentations of preclinical data exploring spinal fusion and bone
cancer indications at ASBMR 2022:
Poster: Improved Spinal Fusion Through Targeted Delivery of
Abaloparatide
- With more than 400,000 spinal fusions performed in the U.S.
every year, Quince believes there is an opportunity to utilize its
bone-targeting platform to improve patient outcomes in spinal
fusion with its NOV004 targeted therapeutic.
- Quince developed a bone-targeting compound based on acidic
oligopeptides which is designed to stimulate bone growth at spinal
fusion sites.
- In preclinical studies, NOV004 concentrated at spinal fusion
sites to demonstrate accelerated repair in treated animals which
resulted in significantly improved blinded radiographic fusion
scores compared to animals treated with the current standard of
care, bone morphogenic protein-2 (BMP-2).
- In addition, NOV004’s subcutaneous administration would allow
for repeat dosing post operatively compared to current spinal
fusion strategies that generally require surgery to apply the drug
and only allow for one application.
Poster: Evaluating the Efficacy of an Acidic
Oligopeptide-radioisotope Chelator Conjugate to Target and Deliver
Radioactive Agents to Bone Cancers
- With five-year survival rates of less than 20% to 30% in
patients with breast and prostate cancer related bone metastases,
Quince believes there is an opportunity to utilize its
bone-targeting platform to develop targeted radiotherapeutics to
improve patient outcomes in breast and bone cancer related bone
tumor growth.
- Quince developed a radioactive acidic oligopeptide conjugate to
target and deliver imaging and therapeutic agents with high
tumor-bearing bone specificity.
- In preclinical studies, the company confirmed that its
targeting moiety can localize to metastatic tumor sites in both
osteolytic and osteoblastic lesions and can selectively deliver
both fluorescent dye and radioisotope-chelated agents without
obvious offsite localization.
- In addition to demonstrating rapid renal excretion, the
radioactive conjugates were retained in the diseased bone even at
two weeks post injection.
To view the posters presented at ASBMR 2022, please visit the
Science section of Quince’s corporate website.
About Quince Therapeutics
Quince Therapeutics is focused on advancing innovative precision
therapeutics targeting debilitating and rare diseases. The company
discovered a broad bone-targeting drug platform designed to
precisely deliver small molecules, peptides, or large molecules
directly to the site of bone fracture and disease to promote more
rapid healing with fewer off-target safety concerns compared to
non-targeted therapeutics. Quince’s discovery pipeline is
positioned for rapid expansion across multiple skeletal therapeutic
indications to address underserved therapeutic areas with major,
unmet medical needs, including osteogenesis imperfecta, fractures,
spinal fusion, and other severe bone diseases. The company’s lead
compound NOV004 is an anabolic peptide engineered to precisely
target and concentrate at the bone fracture site, which preclinical
studies demonstrate result in rapid increases in bone density,
strength, and healing directly at the site of bone fracture. NOV004
is expected to enter Phase 1 clinical studies in 2023 and advance
to a lead indication in osteogenesis imperfecta. For more
information, visit www.quincetx.com and follow Quince Therapeutics
on LinkedIn and @Quince_Tx on Twitter.
Forward-looking Statements
Statements in this news release contain “forward-looking
statements” that are subject to substantial risks and
uncertainties. Forward-looking statements contained in this news
release may be identified by the use of words such as “anticipate,”
“expect,” “will,” “can,” “may,” “should,” “estimate,” “project,”
“potential,” “encouraged,” “positioned,” or other similar words.
Examples of forward-looking statements include, among others, the
clinical development and strategic development path for NOV004; the
timing and success of the company’s clinical trials and related
data, including plans and the ability to initiate, conduct and/or
complete the Phase 1 clinical studies for NOV004; the potential
therapeutic benefits, safety, and efficacy of the company’s
bone-targeting platform, product candidate and discovery pipeline.
Forward-looking statements are based on Quince Therapeutic’s
current expectations and are subject to inherent uncertainties,
risks, and assumptions that are difficult to predict and could
cause actual results to differ materially from what the company
expects. Further, certain forward-looking statements are based on
assumptions as to future events that may not prove to be accurate.
Factors that could cause actual results to differ include, but are
not limited to, the risks and uncertainties described in the
section titled “Risk Factors” in the company’s Annual Report on
Form 10-K filed with the Securities and Exchange Commission (SEC)
on March 1, 2022, its Quarterly Report on Form 10-Q filed with the
SEC on August 9, 2022, and other reports as filed with the SEC.
Forward-looking statements contained in this news release are made
as of this date, and Quince Therapeutics undertakes no duty to
update such information except as required under applicable
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220912005365/en/
Quince Therapeutics Contact: Stacy Roughan Quince
Therapeutics, Inc. Vice President, Corporate Communications &
Investor Relations ir@quincetx.com
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Quince Therapeutics (NASDAQ:QNCX)
Historical Stock Chart
From Apr 2023 to Apr 2024